Primary Indication: Diluent for intrathecal administration of methotrexate sodium and cytarabine for the prevention or treatment of meningeal leukemia or lymphocytic lymphoma Approval Date: FDA Approval -- September 27, 1996 How Supplied: 10 mL single-use ampules, packaged 10 amps per box and 20 boxes per case National Drug Code: 67871-007-10 Shelf-life: 60 months from date of manufacture Storage: Store at controlled room temperature, 20°-25°C (68°C -77°F) Availability: By prescription from any licensed pharmaceutical supplier

What is the stability of methotrexate and cytarabine in Elliotts B® Solution? Methotrexate 3mg/mL and Cytarabine 2mg/mL reconstituted in Elliotts B® Solution and stored in glass vials with plastic syringes have demonstrated to be physically and chemically stable for at least 48 hours at both 4oC and 23oC. However, intrathecal administration of such admixtures should be completed within several hours of preparation, as Elliotts B® Solution does not contain any bacteriostatic preservatives. (Monograph Reference: Data on file)

How can I order Elliotts B® Solution? Please call 1-866-528-4750 or fax 1-866-528-4749

Literature List: Cancer Facts & Figures 1996. Atlanta, GA: American Cancer Society, Inc.; 1996. Miller BA, Ries LAG, Hankey BF et al (eds). Cancer Statistics Review: 1973-1990. Bethesda, MD: National Cancer Institute; 1993. National Institutes of Health publication 93-2789. Geiser CF, Bioshop Y, Jaffe N. Furman L, Traggis D, Frie E. Adverse effects of intrathecal methotrexate in children with acute leukemia in remission. Blood. 1975;45 (2): 189-195. See monograph reference list for additional references